Taking a break from treatment based on ctDNA-MRD for advanced HER2+ breast cancer
Part of Cancer, Skin clinical trials.
This study is for people with advanced HER2-positive breast cancer whose tumors have completely disappeared after recent treatment. It tests whether taking a break from treatment is safe when a special blood test (ctDNA-MRD) shows no trace of cancer remaining.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer is HER2-positive (a type that may be treated with certain targeted drugs).
- Your cancer has spread to other parts of the body (advanced stage).
- After your last treatment, scans showed no sign of cancer for at least 3 months.
- A blood test called ctDNA-MRD shows no cancer cells left in your blood.
- Your blood level of CA15-3 (a tumor marker) is normal.
- You are able to take care of yourself and are generally in good health (ECOG 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood test (ctDNA) can help doctors monitor how well chemotherapy before surgery is working in women with HER2-positive breast cancer. It aims to see if changes in the blood can predict treatment success.
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
This study tests a new blood test to see if it can find tiny bits of tumor DNA after chemotherapy. If you have a larger or higher-risk breast cancer and are getting chemotherapy before surgery, you may join. The test could help doctors know if your cancer is gone or if more treatment is needed.
This trial is testing whether monitoring ctDNA (genetic material from the tumor in your blood) can help guide treatment for HER2-positive breast cancer before surgery. It is for people with early-stage (Stage II or III) disease who have not yet started treatment.
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.